Pharmaceutical combinations containing 6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethylethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one for treating respiratory diseases

摘要

Disclosed is a medicament combination which comprises 6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethylethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one (as represented by the formula 1.5) and one or two compounds as another active substance 2 selected from anticholinergics (2a) and steroids (2c); wherein any anticholinergic (2a) is selected from the group comprising tiotropium salts (2a.1), oxitropium salts (2a.2), flutropium salts (2a.3), ipratropium salts (2a.4), glycopyrronium salts (2a.5), trospium salts (2a.6) and any steroid 2c is selected from the group comprising prednisolone (2c.1), prednisone (2c.2), butixocortpropionate (2c.3), flunisolide (2c.5), beclomethasone (2c.6), triamcinolone (2c.7), budesonide (2c.8), fluticasone (2c.9), mometasone (2c.10), ciclesonide (2c.11), rofleponide (2c.12), dexamethasone (2c.14), (S)-fluoromethyl 6a,9a-difluoro-17a-[(2-furanylcarbonyl)oxy]-11b-hydroxy-16a-methyl-3-oxo-androsta-1,4-diene-17b-carbothionate (2c.15), (S)-(2-oxo-tetrahydro-furan-3S-yl) 6a,9a-difluoro-11b-hydroxy-16a-methyl-3-oxo-17a-propionyloxy-androsta-1,4-diene-17b-carbothionate (2c.16) and etiprednol-dichloroacetate (2c.17), optionally in the form of a racemate, enantiomer or diastereomer thereof and optionally in the form of a salt or functional derivative thereof, solvate and/or hydrate thereof. Also disclosed is the use of a medicament combination as defined above for preparing a pharmaceutical composition for the treatment of inflammatory and obstructive respiratory complaints (such as obstructive pulmonary diseases of various origins, pulmonary emphysema of various origins, restrictive pulmonary diseases, interstitial pulmonary diseases, cystic fibrosis, bronchitis of various origins, bronchiectasis, ARDS (adult respiratory distress syndrome) and all forms of pulmonary oedema , bronchial asthma, paediatric asthma, severe asthma, acute asthma attacks, chronic bronchitis and COPD (chronic obstructive pulmonary disease)).